Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk | Zendy

Amit Khera | Zendy; Brendan M. Everett | Zendy; Michael P. Caulfield | Zendy; Feras M. Hantash | Zendy; Jay G. Wohlgemuth | Zendy; Paul M. Ridker | Zendy; Samia Mora | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk

Author(s) -

Amit Khera,

Brendan M. Everett,

Michael P. Caulfield,

Feras M. Hantash,

Jay G. Wohlgemuth,

Paul M. Ridker,

Samia Mora

Publication year - 2013

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.113.004406

Subject(s) - medicine , rosuvastatin , residual risk , lipoprotein , rosuvastatin calcium , atherosclerotic cardiovascular disease , lipoprotein(a) , cardiology , cholesterol , disease

Lipoprotein(a) [Lp(a)] is a low-density lipoprotein-like particle largely independent of known risk factors and predictive of cardiovascular disease. Statins may offset the risk associated with elevated Lp(a), but it is unknown whether Lp(a) is a determinant of residual risk in the setting of low low-density lipoprotein cholesterol after potent statin therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research